Boston Advisors LLC lowered its position in Icon PLC (NASDAQ:ICLR) by 43.0% during the second quarter, Holdings Channel reports. The firm owned 241,307 shares of the company’s stock after selling 182,147 shares during the period. Boston Advisors LLC’s holdings in Icon PLC were worth $16,894,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Invictus RG bought a new stake in Icon PLC during the first quarter valued at $136,000. Creative Planning increased its stake in Icon PLC by 91.1% in the second quarter. Creative Planning now owns 2,073 shares of the company’s stock valued at $145,000 after buying an additional 988 shares during the last quarter. Acrospire Investment Management LLC bought a new stake in Icon PLC during the first quarter valued at $158,000. Groesbeck Investment Management Corp NJ bought a new stake in Icon PLC during the first quarter valued at $267,000. Finally, GW&K Investment Management LLC bought a new stake in Icon PLC during the second quarter valued at $284,000. Hedge funds and other institutional investors own 93.75% of the company’s stock.
Icon PLC (NASDAQ:ICLR) remained flat at $76.48 during trading on Friday. 331,137 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $76.14 and its 200 day moving average price is $71.67. Icon PLC has a 52-week low of $62.31 and a 52-week high of $79.61. The company has a market capitalization of $4.24 billion, a PE ratio of 17.68 and a beta of 0.92.
Icon PLC (NASDAQ:ICLR) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $1.14 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.14. Icon PLC had a net margin of 15.70% and a return on equity of 29.89%. The firm earned $411 million during the quarter, compared to the consensus estimate of $409.97 million. During the same quarter in the previous year, the firm posted $0.95 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. Analysts anticipate that Icon PLC will post $4.70 EPS for the current year.
Several analysts recently weighed in on ICLR shares. Credit Suisse Group AG started coverage on Icon PLC in a research note on Monday, June 20th. They issued an “outperform” rating and a $80.00 price target on the stock. Avondale Partners downgraded Icon PLC from a “market perform” rating to an “underperform” rating and cut their price target for the stock from $70.00 to $59.00 in a research note on Wednesday, June 8th. Robert W. Baird restated an “outperform” rating and issued a $83.00 price target on shares of Icon PLC in a research note on Monday, June 27th. KeyCorp restated a “buy” rating and issued a $85.00 price target on shares of Icon PLC in a research note on Wednesday, July 27th. Finally, Jefferies Group upped their price target on Icon PLC from $78.00 to $80.00 and gave the stock a “hold” rating in a research note on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $78.19.
About Icon PLC
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon PLC (NASDAQ:ICLR).
Receive News & Ratings for Icon PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon PLC and related companies with MarketBeat.com's FREE daily email newsletter.